Lupin Limited
LUPIN · NSE
Public Market Listing
Live quotes, historical charts, and market capitalization for Lupin Limited are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | beta-2 adrenergic receptor | Asthma | |
| Approved | VEGF-AMonoclonal antibody | Age-Related Macular DegenerationDiabetic Macular Edema | |
| Phase 3 | GLP-1 receptorPeptide | ObesityType 2 Diabetes |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | $3.2B | $233M | — | — | report ↗ |